Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02639546 | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors(iMATRIXcobi) | completed | Phase 1 / Phase 2 | 56 | Hoffmann-La RocheINDUSTRY | 7 | Sep 16, 2022 | clinicaltrials |
| NCT04571632 | Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors(Luscid) | unknown | Phase 2 | 36 | Universitair Ziekenhuis BrusselOTHER |
| 1 |
| Sep 14, 2022 |
| clinicaltrials |
| NCT05530200 | PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors. | unknown | Phase 2 | 56 | Second Affiliated Hospital of Soochow UniversityOTHER | 0 | Sep 7, 2022 | clinicaltrials |
| NCT05527821 | Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors | unknown | Phase 2 | 36 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05528406 | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation | unknown | Phase 2 | 30 | Shanghai Henlius BiotechINDUSTRY | 0 | Sep 6, 2022 | clinicaltrials |
| NCT03455140 | A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)(PARC) | completed | Phase 1 / Phase 2 | 49 | University of BirminghamOTHER | 3 | Sep 2, 2022 | clinicaltrials |
| NCT05524194 | 6MW3511 in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 272 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 0 | Sep 1, 2022 | clinicaltrials |
| NCT05512780 | Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer | unknown | Phase 2 | 30 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 23, 2022 | clinicaltrials |
| NCT05508659 | A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 128 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 19, 2022 | clinicaltrials |
| NCT05505877 | Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 160 | Shanghai Gopherwood Biotech Co., Ltd.INDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04892498 | Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0) | unknown | Phase 2 | 66 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT02130466 | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | completed | Phase 1 / Phase 2 | 184 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 1, 2022 | clinicaltrials |
| NCT05478785 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT02700308 | A Study of Kyphoplasty and Vertebroplasty in the Treatment of Spine Metastases(KYPHO-01) | terminated | Phase 2 | 31 | Centre Leon BerardOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05320588 | A Study in Patients With Advanced Cancers | recruiting | Phase 1 / Phase 2 | 332 | BiOneCure Therapeutics Inc.INDUSTRY | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04315246 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) | withdrawn | Phase 1 / Phase 2 | 0 | Y-mAbs TherapeuticsINDUSTRY | 2 | Jul 15, 2022 | clinicaltrials |
| NCT03427320 | Imaging of Advanced Tumours Using [131]I-IAZA | withdrawn | Phase 1 / Phase 2 | 0 | University of AlbertaOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT03758664 | Clinical Study of ICP-192 in Solid Tumors Patients | unknown | Phase 1 / Phase 2 | 56 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05349409 | A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers | unknown | Phase 2 | 212 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02303028 | Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours(TOPAZ) | completed | Phase 1 / Phase 2 | 30 | The Hospital for Sick ChildrenOTHER | 1 | Jun 28, 2022 | clinicaltrials |
| NCT00073892 | PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 44 | Cellxpert Biotechnology Corp.INDUSTRY | 2 | Jun 27, 2022 | clinicaltrials |
| NCT05019794 | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations(FGFR) | unknown | Phase 2 | 80 | LianBio LLCINDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT03913741 | A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies(innovaTV 206) | completed | Phase 1 / Phase 2 | 23 | GenmabINDUSTRY | 1 | Jun 23, 2022 | clinicaltrials |
| NCT02880371 | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 82 | PfizerINDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT02447419 | Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors | completed | Phase 2 | 16 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05216965 | A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 208 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jun 15, 2022 | clinicaltrials |
| NCT05165849 | A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Zhejiang Genfleet Therapeutics Co., Ltd.INDUSTRY | 0 | May 20, 2022 | clinicaltrials |
| NCT03551795 | Clinical Research on Comprehensive Treatment of Tuberculosis With Malignant Solid Tumor | completed | Phase 1 / Phase 2 | 8 | Xiaoyan ZhangOTHER_GOV | 1 | May 9, 2022 | clinicaltrials |
| NCT04200404 | A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CStone PharmaceuticalsINDUSTRY | 1 | May 6, 2022 | clinicaltrials |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | completed | Phase 1 / Phase 2 | 48 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT04082910 | Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05322720 | HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy | unknown | Phase 2 | 50 | Taizhou EOC Pharma Co., Ltd.INDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT05320640 | Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05322187 | Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy(sPLENTY-pc) | unknown | Phase 2 / Phase 3 | 15 | RenJi HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05218148 | SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma | unknown | Phase 2 | 44 | Aiping ZhouUNKNOWN | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04809012 | Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors | withdrawn | Phase 2 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | Mar 25, 2022 | clinicaltrials |
| NCT00855803 | Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis | completed | Phase 2 | 35 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT05258266 | A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 76 | Nanjing Zenshine PharmaceuticalsINDUSTRY | 1 | Mar 14, 2022 | clinicaltrials |
| NCT05274191 | An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors | unknown | Phase 2 | 60 | Zhongshan Hospital Xiamen UniversityOTHER | 0 | Mar 10, 2022 | clinicaltrials |
| NCT01515306 | A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors | completed | Phase 2 | 48 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03454620 | A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy | completed | Phase 1 / Phase 2 | 53 | Green Cross CorporationINDUSTRY | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03347123 | A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) | terminated | Phase 1 / Phase 2 | 11 | Incyte CorporationINDUSTRY | 1 | Feb 28, 2022 | clinicaltrials |
| NCT05254665 | A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors | unknown | Phase 2 | 110 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 24, 2022 | clinicaltrials |
| NCT03868423 | Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers | withdrawn | Phase 2 | 0 | Sameek RoychowdhuryOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03865082 | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | active not recruiting | Phase 2 | 30 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT01295697 | Study of EZN-2208 Pediatric Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 32 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02460224 | Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 / Phase 2 | 490 | Novartis PharmaceuticalsINDUSTRY | 12 | Feb 10, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Sep 16, 2022source: clinicaltrials